About this episode
President Trump has issued an executive order to speed up reviews into psychedelic drugs like psilocybin, LSD, and Ibogaine. Psychedelics are banned in the US in the vast majority of circumstances, but scientists are looking at the drugs and their possible therapeutic benefits for serious mental health conditions.
Ibogaine comes from a shrub native to west Africa and is used ceremonially in Gabon. Trials have reported benefits from the drugs in conditions like post-traumatic stress disorder and opioid addiction. But experts say that it’s been difficult to study because it can cause heart problems.
BBC’s Bernd Debussman Jr in Washington tells us more about the growing interest in psychedelics in the US. Plus, we hear about the reaction in Gabon from Yann Guignon, a researcher at Blessings Of The Forest, a charity that works to protect Gabonese cultural heritage.
Instagram: @bbcwhatintheworld Email: [email protected] WhatsApp: +44 330 12 33 22 6 Presenter: Hannah Gelbart Producer: Emily Horler, Chelsea Coates and Benita Barden Editor: Harriet Oliver
Get every episode summarized
Each time What in the World publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from What in the World
We should all appreciate vultures more!
What in the World
How does nine months at sea impact your mental health?
What in the World
Peekaboo! The story of Canada’s moving island
What in the World
What’s the right way to address your boss?
What in the World